CNBC December 20, 2024
Annika Kim Constantino

Key Points

– The Food and Drug Administration approved Eli Lilly’s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder.

– The weekly injection is now the first drug treatment option cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, which refers to breathing interrupted during sleep due to narrowed or blocked airways.

– The agency’s decision expands the use of Zepbound and could pave the way for Eli Lilly to gain broader insurance coverage for the treatment.

The Food and Drug Administration on Friday approved Eli Lilly‘s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, expanding its use and possibly its insurance coverage in the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old
U.S. Health Care Spending Reaches $4.9 Trillion
Medicaid spending on weight loss, diabetes drugs up 500% since 2019: 5 numbers to know
How has U.S. Spending on Health Care Changed Over Time?

Share This Article